BrightFocus Foundation forms strategic partnerships with like-minded organizations to promote research and educational efforts related to brain and eye diseases.


 

21st Century BrainTrust™

21st Century BrainTrust logo.

The Geoffrey Beene Foundation Alzheimer’s Initiative led the formation of the 21st Century BrainTrust™ (21CBT) in 2012 with BrightFocus Foundation, UsAgainstAlzheimer's, and scientific partner Cleveland Clinic/Lou Ruvo Brain Institute.

21CBT is a virtual research ecosystem designed to empower personal brain health and support early diagnosis using self-administered mobile applications for personal measurement and monitoring of cognition.

21CBT promotes novel technologies that offer low-cost screening capabilities for future prevention trials to facilitate enrollment as well as exploratory trial endpoints.

 


 

Alzheimer's Disease Big Data DREAM Challenge #1

A cross-section image of a brain and the following text: Alzheimer's Disease Big Data DREAM -- Challenge #1.

BrightFocus Foundation is one of several non-profit and industry supporters of the Alzheimer’s Disease Big Data DREAM Challenge #1, an effort to apply an open science approach to rapidly identify accurate biomarkers for Alzheimer’s disease. Information would then be shared and used by the scientific, industrial, and regulatory communities to improve Alzheimer’s diagnosis and treatment.

The focus of this Challenge, first announced at the White House last year, is to have different scientists predict the best biomarkers for early Alzheimer's disease-related cognitive decline, and to address the “mismatch” between cognitive decline and high amyloid levels.

 


 

American Glaucoma Society

 

American Glaucoma Society logo

BrightFocus collaborates with the American Glaucoma Society, which is comprised of Glaucoma Specialists dedicated to sharing clinical and scientific information for the benefit of patients, colleagues, fellows and residents, to produce the BrightFocus Glaucoma Chats series.

 


 

Geoffrey Beene Foundation Alzheimer's Initiative

Geoffrey Beene Foundation Alzheimer's Initiative logo.

BrightFocus Foundation is a mission partner of the Alzheimer's Initiative of the Geoffrey Beene Foundation. The Initiative is a philanthropic, not for-profit 501(c)(3), committed to providing catalyst funding to innovative new projects that advance awareness, diagnosis and research in early stages of Alzheimer's disease.

The Geoffrey Beene Foundation Alzheimer's Initiative reaches across disciplines and industries through awards-based, open source challenges that engage new leaders with new ideas about our nation's aging population and how to accelerate the development of Alzheimer's therapies.

 


 

LEAD

LEAD logo.

BrightFocus Foundation is a member of Leaders Engaged on Alzheimer’s Disease (LEAD), a diverse and growing national coalition of 67 organizations including patient advocacy and voluntary health non-profits, philanthropies and foundations, trade and professional associations, academic research and clinical institutions, home and residential care providers, and biotechnology and pharmaceutical companies.  

The coalition works collaboratively to focus the nation’s strategic attention on Alzheimer’s disease and related disorders and to accelerate transformational progress in care and support, detection and diagnosis, and research leading to prevention, effective treatment, and eventual cure.

 



Molecular Neurodegeneration

Molecular Neurodegeneration logo.

BrightFocus Foundation has entered into a partnership with BioMed Central's open access journal, Molecular Neurodegeneration (MN), in which MN is now the official journal of BrightFocus. The open access publishing model provides articles for free to the general public as well as scientists, clinicians and other healthcare practitioners.

Molecular Neurodegeneration publishes peer-reviewed, original scientific research on the causes of neurodegenerative diseases, like Alzheimer's or Parkinson's, and on the pre-clinical testing of potential therapies for these devastating diseases. According to the ISI Web of Knowledge by Thomson Reuters, MN was ranked in the top 16 percent of journals among the 'neurosciences' category (debuted with a 5.09 impact factor). The current impact score is 5.29.

 


 

National Eye Health Education Program

 

National Eye Health Education Program (NEHEP) logo

BrightFocus is an Ambassador Partner of the National Eye Health Education Program (NEHEP) Partnership housed at the National Eye Institute, a national network of more than 60 public and private organizations committed to eye health education. NEHEP works closely with health professionals and health educators to create resources and tools used to raise awareness in communities around the country.

 



ReACT

React logo.

BrightFocus Foundation is a member of ReACT, an employer-focused coalition dedicated to addressing the challenges faced by employee caregivers and reducing the impact on the companies that employ them.

ReACT represents nearly 1 million employees through its membership of more than 30 companies and non-profit organizations.




Rendia

 Rendia logo.

BrightFocus Foundation is a mission partner with Rendia, a healthcare media company focused on solutions that support professionals, patients, and corporations in communicating and understanding complex medical topics.

The company’s in-depth experience with animation, design, and software has enabled Rendia to create integrated systems that provide clear and concise education solutions. Rendia reflects the intersection where intention, action, and technology meet, bridging the communication gap between doctors and patients to build better relationships and improve patient outcomes.



 

UsAgainstAlzheimer’s

 

usagainstalz logo

BrightFocus Foundation, a member of Leaders Engaged on Alzheimer’s Disease (LEAD) and a founding partner of the21st Century BrainTrust™ (21CBT), is proud to be part of the UsAgainstAlzheimer’s network of organizations that serve the Alzheimer’s community and support innovative Alzheimer’s research and drug discovery.